Cost and consequences of noncompliance to oral bisphosphonate treatment

Journal of Managed Care Pharmacy

Volumn 21, Issue 1, 2015, Pages 56-65

  Eisenberg, Debra F ^a   Placzek, Hilary ^a   Gu, Tao ^a   Krishna, Arun ^a   Tulsi, Bernard B ^b  

^a HEALTHCORE INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; TREATMENT REFUSAL; COST BENEFIT ANALYSIS; ECONOMICS; FRACTURES, BONE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT ATTITUDE; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; MALE; MEDICATION COMPLIANCE; PATIENT EDUCATION; PREFERRED PROVIDER ORGANIZATION; PRESCRIPTION;

ADMINISTRATION, ORAL; AGED; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; LINEAR MODELS; MIDDLE AGED; OSTEOPOROSIS; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84925300365     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.1.56     Document Type: Article

References (19)

1. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2013.
2. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004.
3. Cosman F. The prevention and treatment of osteoporosis: a review. MedGenMed. 2005;7(2):73.
4. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. Washington, DC: National Osteoporosis Foundation; 2002.
5. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20(10):1633-50.
6. Colón-Emeric C, Kuchibhatla M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int. 2003;14(11):879-83.
7. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-75.
8. Fleurence RL, Iglesias CP, Johnson JM. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics. 2007;25(11):913-33.
9. Levis S, Theodore G. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm. 2012;18(4 Suppl B):S1-S15. Available at: http://www.ahrq.gov/professionals/education/continuing-ed/index.html.
10. Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005;9(22):1-160.
11. Tosteson AN, Burge RT, Marshall DA, Lindsay R. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations. Am J Manag Care. 2008;14(9):605-15.
12. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453-60.
13. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38(9):922-28.
14. Reynolds K, Muntner P, Cheetham TC, et al. Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int. 2013;24(9):2509-17.
15. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013-22.
16. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023-31.
17. Gold DT, Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep. 2006;4(1):21-27.
18. Gold DT. Understanding patient compliance and persistence with osteoporosis therapy. Drugs Aging. 2011;28(4):249-55.
19. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-19.